目的:本研究使用来自大量未经选择的周围性面瘫患者队列的回顾性纵向数据,以确定接受干预的后遗症的患病率和患者特征预测因素。
方法:回顾性病例回顾。
方法:瑞典斯德哥尔摩卡罗林斯卡大学医院是该地区唯一的三级面神经麻痹中心。这里,患者被诊断,被跟进,并接受所有重大干预。
方法:所有因特发性而出现周围性面神经麻痹的成年患者,带状疱疹,或者起源于卡罗林斯卡的疏螺旋体,2010年1月1日至2011年12月31日,随访至2022年12月。
方法:研究了患者图表以确定患者特征,病因学,初始治疗,麻痹的严重程度,和针对后遗症的治疗。
方法:记录初始和晚期治疗的类型。Sunnybrook和/或House-Brackmann量表用于麻痹分级。
结果:纳入了125名患者。33例患者(6.3%)接受肉毒杆菌毒素注射和/或手术治疗。在这个子群中,67%的患者接受皮质类固醇治疗,而85%的患者接受皮质类固醇治疗(p=0.005)。心血管疾病患病率更高(23%和42%,分别,p=0.009)。81名患者(15%)尽管最后一次测量是Sunnybrook小于70或House-Brackmann3至6,但随访仍停止。
结论:周围性面神经麻痹患者,6.3%在12年内接受了注射和/或手术治疗。然而,由于相当大的比例没有提出后续行动,这可能是一种低估。接受晚期注射和/或手术治疗的患者有更多的合并症,并且在疾病的急性期接受皮质类固醇治疗的程度明显较低。
OBJECTIVE: This study uses retrospective longitudinal data from a large unselected cohort of patients with peripheral facial paralysis to determine the prevalence and patient characteristic predictors of sequelae receiving intervention.
METHODS: Retrospective case review.
METHODS: Karolinska University Hospital in Stockholm Sweden serves as the only tertiary facial palsy center in the region. Here, patients are diagnosed, are followed up, and undergo all major interventions.
METHODS: All adult patients presenting with peripheral facial palsy due to idiopathic, zoster, or Borrelia origin at Karolinska, January 1, 2010 to December 31, 2011 with follow-up until December 2022.
METHODS: Patient charts were studied to identify patient characteristics, etiology, initial treatment, severity of palsy, and treatments targeting sequelae.
METHODS: Types of initial and late treatments were noted. Sunnybrook and/or House-Brackmann scales were used for palsy grading.
RESULTS: Five hundred twenty-five patients were included. Thirty-three patients (6.3%) received botulinum toxin injections and/or surgical treatment. In this subgroup, 67% received corticosteroids compared to 85% of all patients ( p = 0.005), cardiovascular disease prevalence was higher (23 and 42%, respectively, p = 0.009). For 81 patients (15%), follow-up was discontinued although the last measurement was Sunnybrook less than 70 or House-Brackmann 3 to 6.
CONCLUSIONS: Of patients with peripheral facial palsy, 6.3% underwent injections and/or surgical treatment within 12 years. However, due to a rather large proportion not presenting for follow-up, this might be an underestimation. Patients receiving late injections and/or surgical treatment had more comorbidities and received corticosteroid treatment to a significantly lower extent in the acute phase of disease.